GU CONNECT Prostate Cancer Update from ESMO 2016 (1/3)
GU CONNECT Prostate Cancer Update from ESMO 2016 (1/3)
Assoc. Prof. Tanya Dorff
GU CONNECT has summarised the prostate cancer highlights from ESMO 2016 - Copenhagen for you.Assoc. Prof. Tanya Dorff
Medical Oncologist
City of Hope Comprehensive Cancer Center
United States (US)
Following a residency at Mt. Sinai Hospital in New York City, Dr. Dorff came to LAC + USC Medical Center for her hematology and medical oncology fellowship. She currently heads the Genitourinary group within the Department of Medical Oncology at the City of Hope Comprehensive Cancer Center. In addition to being a devoted clinician and translational researcher, Dr. Dorff has authored more than 45 peer reviewed articles as well as 35 review articles/commentaries. Dr. Dorff serves as an associate editor for Clinical Genitourinary Cancer and Seminars in Urologic Oncology. She has lectured on prostate and bladder cancer treatment nationally and internationally and has presented her research at national meetings. Current research interests include the effects of fasting on chemotherapy side effects and cancer control and immunotherapy for prostate cancer. She has been the principal investigator for more than a dozen clinical trials, involving targeted therapy and immunotherapy, for genitourinary cancers.
Assoc. Prof. Tanya Dorff has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Astellas, Exelixis, Janssen and SeaGen.
|
5 min
|
Sep 2016
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Prostate cancer update by Asst. Prof. Tanya Dorff
GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.